Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial

OBJECTIVE: Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of insulin degludec (70%) and insulin aspart (IAsp: 30%). Here, we compare the efficacy and safety of IDegAsp, an alternative IDegAsp formulation (AF: containing 45% IAsp), and biphasic IAsp 30 (BIAsp 30). DESIGN: Sixte...

Descripción completa

Detalles Bibliográficos
Autores principales: Niskanen, Leo, Leiter, Lawrence A, Franek, Edward, Weng, Jianping, Damci, Taner, Muñoz-Torres, Manuel, Donnet, Jean-Paul, Endahl, Lars, Skjøth, Trine Vang, Vaag, Allan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioScientifica 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400040/
https://www.ncbi.nlm.nih.gov/pubmed/22660026
http://dx.doi.org/10.1530/EJE-12-0293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400040/
https://www.ncbi.nlm.nih.gov/pubmed/22660026
http://dx.doi.org/10.1530/EJE-12-0293

Ejemplares similares